Shares of BSX Up 27.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 10, 1:14PM CDT
SmarTrend identified an Uptrend for Boston Scientific (NYSE:BSX) on March 14th, 2016 at $18.01. In approximately 3 months, Boston Scientific has returned 27.60% as of today's recent price of $22.98.
BSX: 23.02 (-0.30)
India Peripheral Vascular Devices Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Medtronic, Boston Scientific, Terumo - Research and Markets
BusinessWire - Fri Jun 10, 10:31AM CDT
Research and Markets has announced the addition of the "India Peripheral Vascular Devices Market Outlook to 2021" report to their offering.
BSX: 23.02 (-0.30), MDT: 85.70 (-0.08)
Global Spinal Cord Stimulation Market Report: 2016 Edition Featuring Medtronic Plc., Nevro Corporation, Boston Scientific, and St. Jude Medical - Research and Markets
BusinessWire - Fri Jun 10, 4:29AM CDT
Research and Markets has announced the addition of the "Global Spinal Cord Stimulation Market Report: 2016 Edition" report to their offering.
BSX: 23.02 (-0.30), MDT: 85.70 (-0.08), NVRO: 72.83 (-2.89)
After Yesterday's Rally of 2.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jun 09, 12:02PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $22.76 to a high of $23.28. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $22.92 on volume of 11.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BSX: 23.02 (-0.30)
Watch for Shares of Boston Scientific (BSX) to Approach Resistance at $23.16
Comtex SmarTrend(R) - Thu Jun 09, 9:22AM CDT
Shares of Boston Scientific (NYSE:BSX) opened today above their pivot of $22.74 and have already reached the first level of resistance at $22.98. Should the shares continue to rise, the resistance pivots of $23.16 and $23.58 will be of interest.
BSX: 23.02 (-0.30)
Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), HAE: 29.58 (-0.14), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06)
Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation
PR Newswire - Wed Jun 08, 5:30PM CDT
Boston Scientific Corporation (NYSE: BSX) today announced a global restructuring program to build on the progress the company has made in executing long-term growth strategies and bringing differentiated value and innovation to patients and healthcare systems. The program is focused on developing global commercialization, technology and manufacturing capabilities in key growth markets, continuing implementation of the company's plant network optimization strategy and expanding operational efficiencies in support of the company's operating income margin goals.
BSX: 23.02 (-0.30)
Hill-Rom: Welch-Allyn Buyout Drives Q2, Forex Woes Stay
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:20AM CDT
Hill-Rom (HRC) posted a mixed second quarter of fiscal 2016 with the bottom line surpassing the Zacks Consensus Estimate and the top line missing the same.
BSX: 23.02 (-0.30), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06), HRC: 50.10 (-1.12)
Zimmer Biomet's Spine Business to Get a Boost with LDR Buy
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 6:00AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) has entered into a definitive agreement to acquire LDR Holding Corp. (LDRH) for a total deal value of $1 billion.
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), ZBH: 119.23 (-0.17), LDRH: 36.98 (+0.07)
Buy These 5 Stocks with Explosive Earnings Growth
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 11:51AM CDT
From CEOs to research analysts, everyone is fascinated with a metric called earnings.
BSX: 23.02 (-0.30), CPRT: 49.02 (-0.97), EEFT: 78.56 (-2.12), CASY: 119.63 (+0.31), DY: 84.76 (-2.34)
Hologic: Q2 Strong on Segmental Expansion, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:43AM CDT
Hologic (HOLX) ended second-quarter fiscal 2016 on a promising note, squarely beating the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06), HOLX: 34.14 (-0.81)
CVS Health (CVS): Strong Q1, Mega Buyouts Offer Hope
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:24AM CDT
On Jun 7, 2016, we issued an updated research report on CVS Health Corp. (CVS).
BSX: 23.02 (-0.30), HLF: 61.89 (-0.55), BAX: 44.49 (-0.26), CVS: 96.67 (-0.32)
NuVasive to Strengthen Spine Service Line with Biotronic Buy
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:17AM CDT
NuVasive, Inc. (NUVA) recently entered into a definitive agreement to acquire privately held Biotronic NeuroNetwork.
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), BAX: 44.49 (-0.26), NUVA: 58.98 (-1.03)
Mead Johnson: Strong Q1 on Overseas Growth & Strategies
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 6:40AM CDT
Mead Johnson (MJN) embarked on a promising journey this year, posting square beats in the first quarter.
BSX: 23.02 (-0.30), MJN: 83.79 (-0.38), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06)
Henry Schein: Q1 Results Strong, Expansion Plans on Track
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:02AM CDT
Henry Schein (HSIC)made an impressive start to 2016, with its top and bottom line beating the Zacks Consensus Estimate in the first quarter.
BSX: 23.02 (-0.30), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06), HSIC: 178.35 (-2.36)
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26)
Medtronic (MDT) Posts Solid Q4; Covidien Synergy Continues
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 6:31AM CDT
On Jun 3, 2016, we issued an updated research report on Medtronic plc (MDT).
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), MDT: 85.70 (-0.08), LMAT: 15.03 (-0.06)
Boston Scientific Has Returned 27.7% Since SmarTrend Recommendation (BSX)
Comtex SmarTrend(R) - Fri Jun 03, 12:54AM CDT
SmarTrend identified an Uptrend for Boston Scientific (NYSE:BSX) on March 14th, 2016 at $18.01. In approximately 3 months, Boston Scientific has returned 27.69% as of today's recent price of $22.99.
BSX: 23.02 (-0.30)
GNC Holdings Q1 Results Weak, Overseas Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:01AM CDT
GNC Holdings (GNC) made a disappointing start to its first quarter of 2016 with the results squarely missing the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), GNC: 25.65 (-0.52)